|
|
Article: Schering Laboratories Begins CLARINEX(R) DTC Education Program; Consumer Advertising Will Highlight Commitment to Patient-Physician Dialogue and Patient Education on Treatment of Indoor- and Outdoor-Allergies.
- Article from:
- PR Newswire
- Article date:
- March 4, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
KENILWORTH, N.J. -- Schering Laboratories announced that today it initiated a direct-to-consumer (DTC) advertising program to inform consumers about the treatment of allergic rhinitis (AR) and CLARINEX(R) (desloratadine) Tablets, the first and only nonsedating antihistamine approved for the of treatment symptoms caused by year-round indoor allergens and seasonal outdoor allergens. Timed to coincide with the beginning of the spring 2002 allergy season, the education program includes a dedicated Web site, a series of print, broadcast and online advertisements, and information displays for doctors' offices and pharmacies that emphasize Schering Laboratories' commitment to ...